左卡尼汀联合促红细胞生成素治疗肾性贫血临床观察  

Clinic Observation of L-carnitine Combined with Erythropoietin in the Treatment of Renal Anemia

作　　者：车华[1] 苏东东[1] 赵文琪[1] 

机构地区：[1]广州军区武汉总医院血液净化科,武汉430070

出　　处：《中国药师》2011年第7期1023-1024,共2页China Pharmacist

摘　　要：目的:探讨左卡尼汀联合促红细胞生成素治疗肾性贫血的临床疗效。方法:56例血液透析(hemodialysis,HD)伴有肾性贫血的尿毒症患者随机分为治疗组与对照组,每组28例。全部患者均应用促红细胞生成素(EPO)4000u,皮下注射,每周2次。治疗组于HD结束后静脉注射左卡尼汀1.0g,每周2次,疗程12周。所有患者分别记录治疗前和治疗开始后12周的血红蛋白、红细胞压积、C-反应蛋白。结果:两组患者经治疗后,贫血指标均得以改善,但治疗组升高的幅度更明显(P<0.05),炎症指标CRP水平均较治疗前下降,但治疗组下降的幅度更明显(P<0.05)。治疗组总有效率达到92.85%,亦明显高于对照组(P<0.05)。治疗组2例患者出现轻度恶心。结论:左卡尼汀可加强EPO的疗效。左卡尼汀联合EPO治疗肾性贫血安全有效。To investigate the therapeutic effect of L-carnitine combined with erythropoietin in hemodialysis patients with renal anemia. Method： 56 renal anemic patients were randomly divided into the treatment group （TG） and control group （28 cases for each）. 1.0 g L-carnitine injection was intravenously dropped twice a week for the TG patients during the dialysis. All the patients were treated with erythropoietin and observed for 12 weeks. The changes in Hb, HCT and serum C-reactive protein （CRP） levels and side effects were monitored. Result： Hb, HCT and CRP levels were improved in both groups after the treatment. However, Hb and HCT levels in the TG were significantly higher than those in the control group （P 〈 0. 05 ）. CRP levels in the TG were significantly de- pressed than those in the control group （ P 〈 0. 05 ）. The total effective rate of the TG was 92. 85% which was significantly higher than that of the control group （P 〈0. 05）. The side effect （nausea） was only shown in 2 patients in the TG. Conclusion： L-carnitine can improve the effect of erythropoietin, and the combinative application is safe and effective for the treatment of renal anemia.

关 键 词：左卡尼汀 促红细胞生成素 肾性贫血 

分 类 号：R977.4[医药卫生—药品]